Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Rhea-AI Summary

Cytokinetics (NASDAQ: CYTK) announced that MYQORZO (aficamten) is now available by prescription in the U.S. in 5 mg, 10 mg, 15 mg and 20 mg tablets following FDA approval on Dec 19, 2025.

MYQORZO is a once-daily oral cardiac myosin inhibitor indicated for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. The prescribing information includes a Boxed WARNING for heart failure risk; initiation is not recommended in patients with LVEF <55% and echocardiogram monitoring is required. MYQORZO is available only through a REMS program. Cytokinetics launched patient support services and specialty pharmacy distribution concurrent with availability.

Positive

• FDA approval secured on Dec 19, 2025
• Commercial launch with tablets in 5, 10, 15, 20 mg strengths
• Once-daily oral therapy addressing oHCM hypercontractility

Negative

• Boxed WARNING for risk of heart failure due to LVEF reduction
• Restricted distribution under a REMS program requiring certified prescribers and pharmacies
• Drug interactions via CYP2C9 (primary) and other CYP pathways may increase heart-failure risk or reduce effectiveness

News Market Reaction – CYTK

+1.30%

6 alerts

+1.30% News Effect

+$104M Valuation Impact

$8.07B Market Cap

0.2x Rel. Volume

On the day this news was published, CYTK gained 1.30%, reflecting a mild positive market reaction. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $104M to the company's valuation, bringing the market cap to $8.07B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Tablet strengths: 5 mg, 10 mg, 15 mg, 20 mg U.S. FDA approval date: December 19, 2025 LVEF initiation threshold: <55% +5 more

8 metrics

Tablet strengths 5 mg, 10 mg, 15 mg, 20 mg MYQORZO U.S. prescription doses

U.S. FDA approval date December 19, 2025 MYQORZO approval for symptomatic obstructive HCM in adults

LVEF initiation threshold <55% Initiation of MYQORZO not recommended if LVEF <55%

Dose reduction LVEF range <50% and ≥40% Decrease MYQORZO dose if LVEF in this range

Dose interruption LVEF threshold <40% Interrupt MYQORZO if LVEF <40% or heart failure symptoms

Hypertension incidence 8% vs 2% Hypertension in MYQORZO vs placebo in pivotal trial

REMS contact phone 1-844-285-7367 MYQORZO REMS Program information line

Pivotal trial SEQUOIA-HCM Phase 3 trial supporting MYQORZO FDA approval

Market Reality Check

Price: $62.42 Vol: Volume 1,131,666 vs 20-da...

low vol

$62.42 Last Close

Volume Volume 1,131,666 vs 20-day average 1,789,945 (relative volume 0.63x). low

Technical Trading at $63.19, above 200-day MA of $47.82 and 10.97% below the 52-week high of $70.98.

Peers on Argus

CYTK slipped 0.35% while close peers showed mixed moves (e.g., AXSM +0.08%, LEGN...

CYTK slipped 0.35% while close peers showed mixed moves (e.g., AXSM +0.08%, LEGN -0.32%, ABVX -0.71%, RYTM +1.18%, NUVL +0.46%). No peers appeared in the momentum scanner, and only AXSM had a same-day earnings-date headline.

Historical Context

5 past events · Latest: Jan 20 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 20	Inducement equity grants	Neutral	-1.2%	New-hire stock options and RSUs granted under Nasdaq inducement rule.
Jan 05	Conference appearance	Neutral	+5.5%	J.P. Morgan Healthcare Conference presentation and webcast announcement.
Dec 19	U.S. FDA approval	Positive	+4.6%	FDA approval of MYQORZO for symptomatic obstructive HCM in adults.
Dec 17	China NMPA approval	Positive	-3.5%	NMPA approval in China with milestone economics and pending U.S./EU reviews.
Dec 16	Inducement equity grants	Neutral	-0.2%	Equity awards to new employees under Nasdaq inducement provisions.

Pattern Detected

Regulatory milestones like FDA and China approvals have drawn mixed reactions, with one approval-day gain and one selloff, while routine corporate items (inducement grants, conference appearances) have generally seen modest moves.

Recent Company History

Over the past months, Cytokinetics has progressed MYQORZO across key regulatory milestones. On Dec 16–20, 2025, it issued inducement equity awards with minor stock reactions. The Dec 17, 2025 NMPA approval in China, which included up to $150M+ in potential milestones and royalties, saw a negative move. By Dec 19, 2025, U.S. FDA approval for MYQORZO produced a positive reaction. A J.P. Morgan conference appearance on Jan 12, 2026 also coincided with a solid gain.

Market Pulse Summary

This announcement marks MYQORZO’s U.S. commercial availability following FDA approval on Dec 19, 202...

Analysis

This announcement marks MYQORZO’s U.S. commercial availability following FDA approval on Dec 19, 2025, transitioning Cytokinetics further into a commercial-stage biotech. The label includes a boxed warning, REMS program, and specific LVEF thresholds guiding dose changes or interruption. Investors may track prescription uptake, safety monitoring requirements, and how this launch builds on earlier approvals, including China and pending European decisions, as MYQORZO’s rollout progresses.

Key Terms

cardiac myosin inhibitor, obstructive hypertrophic cardiomyopathy, left ventricular outflow tract (LVOT), left ventricular ejection fraction (LVEF), +4 more

8 terms

cardiac myosin inhibitor medical

"MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility..."

A cardiac myosin inhibitor is a type of drug that directly reduces the force of heart muscle contractions by blocking the motor protein (myosin) that drives each heartbeat; think of it as slightly easing the pressure on an overworking engine so it doesn’t overexert itself. It matters to investors because these medicines can change treatment options, regulatory pathways, and revenue prospects for companies developing therapies for conditions where the heart is too strong or stressed, while carrying clinical and safety risks that affect valuation.

obstructive hypertrophic cardiomyopathy medical

"...for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM)..."

A heart condition where the muscle of the left ventricle becomes abnormally thick and narrows the pathway blood must flow through, like a pump whose outlet has been partly blocked by swollen walls. It matters to investors because it drives demand for ongoing medical care, devices and drugs, can lead to sudden, costly hospital interventions, and influences the size and urgency of markets for treatments and clinical trials.

left ventricular outflow tract (LVOT) medical

"...reduces cardiac contractility and left ventricular outflow tract (LVOT) obstruction."

The left ventricular outflow tract (LVOT) is the passage in the heart through which oxygen-rich blood leaves the left ventricle and enters the aorta; think of it as the exit ramp from the heart’s main pumping chamber. Investors care because narrowing, obstruction or other problems here drive demand for treatments, devices and procedures, affect patient outcomes and healthcare costs, and therefore influence the market size, regulatory reviews and reimbursement for related products.

left ventricular ejection fraction (LVEF) medical

"MYQORZO reduces left ventricular ejection fraction (LVEF) and can cause heart failure..."

Left ventricular ejection fraction (LVEF) is the percentage of blood the heart’s main pumping chamber pushes out with each beat, a simple measure of how effectively the heart pumps like the efficiency rating on a water pump. Investors care because LVEF is a key clinical indicator used to diagnose and guide treatment for heart failure and other cardiac conditions, which affects demand for drugs, devices, reimbursement, trial outcomes, and company valuation.

risk evaluation and mitigation strategy (rems) regulatory

"...only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS)..."

A Risk Evaluation and Mitigation Strategy (REMS) is a formal safety program required by regulators for certain medicines or medical products to ensure benefits outweigh serious risks. It sets rules—such as training for prescribers, special distribution systems, or monitoring—to reduce harm. For investors, REMS can limit how widely and quickly a product can be sold, raise compliance costs, and affect legal risk, similar to how safety checks can slow and add expense to running a vehicle fleet.

cytochrome p450 medical

"Cytochrome P450 Interactions Leading to Heart Failure or Loss of Effectiveness"

A group of enzymes in the body that act like chemical processing machines, breaking down drugs and other foreign substances so they can be removed. Investors care because these enzymes determine how quickly a drug is cleared, how it interacts with other medicines, and whether dose adjustments or safety warnings are needed—factors that can make or break a drug’s marketability, label restrictions, and regulatory approval.

cyp3a medical

"...by CYP2C9, and to a lesser extent by CYP3A, CYP2D6, and CYP2C19 enzymes."

CYP3A is a group of liver enzymes that act like the body’s chemical processing machines, breaking down many medicines and other foreign substances so they can be removed. Investors care because drugs that are processed by CYP3A can interact with other drugs or require special dosing, affecting safety, regulatory approval, sales potential, and labeling; unexpected metabolism issues can materially change a drug’s market value.

n-terminal pro-b-type natriuretic peptide medical

"...or elevations in N-terminal pro-B-type natriuretic peptide may be signs..."

A blood marker released when the heart is under stress, N-terminal pro-B-type natriuretic peptide (NT-proBNP) helps doctors detect and monitor heart failure and other cardiac strain. Think of it as a dashboard warning light: higher levels signal worse heart function. For investors, NT-proBNP matters because it is widely used in clinical trials, guides treatment decisions, and influences demand for diagnostics, therapies, and reimbursement in the cardiovascular market.

AI-generated analysis. Not financial advice.

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying 
Hypercontractility Associated with Obstructive HCM

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MYQORZO™ (aficamten) is now available for prescription in 5 mg, 10 mg, 15 mg and 20 mg tablets in the U.S. MYQORZO was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.

Experience the full interactive Multichannel News Release here: https://www.multivu.com/cytokinetics/9379451-en-myqorzo-now-available-ohcm.

MYQORZO is a once-daily, oral allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and left ventricular outflow tract (LVOT) obstruction.

“With MYQORZO now available in the U.S., we are delivering on our long-standing commitment to patients living with obstructive HCM and turning the page onto a new chapter as a commercial biopharmaceutical company,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “This product launch is the culmination of decades of rigorous science, clinical development, and commercial readiness preparations, reflecting our unwavering commitment to making a meaningful difference in the lives of patients. We are grateful to the healthcare professionals, patients and advocates across the HCM community whose insights and partnerships helped bring MYQORZO to this important milestone. With our REMS program now live, and our supply chain and specialty pharmacy distribution network fully operational, we are proud to make MYQORZO available as a new treatment option for patients with oHCM.”

The full U.S. Prescribing Information for MYQORZO includes a Boxed WARNING for the risk of heart failure. MYQORZO reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction. Echocardiogram assessments are required prior to and during treatment with MYQORZO to monitor for systolic dysfunction. Initiation of MYQORZO in patients LVEF <55% is not recommended. Decrease the dose of MYQORZO if LVEF <50% and ≥40%. Interrupt the dose of MYQORZO if LVEF <40% or if the patient experiences heart failure symptoms or worsening clinical status due to systolic dysfunction. Because of the risk of heart failure due to systolic dysfunction, MYQORZO is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the MYQORZO REMS Program. Please see additional Important Safety Information including Boxed WARNING below.

Cytokinetics received U.S. FDA approval for MYQORZO on December 19, 2025. The approval was based on the positive results from the pivotal Phase 3 clinical trial, SEQUOIA-HCM, published in the New England Journal of Medicine.¹

Cytokinetics is committed to supporting patients with MYQORZO & You™, a personalized program for patients prescribed MYQORZO in the U.S. to help navigate the treatment journey, provide disease and product education, and offer support with insurance benefits investigations or financial assistance for those eligible.

INDICATION

MYQORZO is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF HEART FAILURE

MYQORZO reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction. Echocardiogram assessments are required prior to and during treatment with MYQORZO to monitor for systolic dysfunction. Initiation of MYQORZO in patients with LVEF <55% is not recommended. Decrease the dose of MYQORZO if LVEF is <50% and ≥40%. Interrupt the dose of MYQORZO if LVEF <40% or if the patient experiences heart failure symptoms or worsening clinical status due to systolic dysfunction. Because of the risk of heart failure due to systolic dysfunction, MYQORZO is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the MYQORZO REMS Program.

CONTRAINDICATIONS

MYQORZO is contraindicated with concomitant use of rifampin.

WARNING AND PRECAUTIONS

Heart Failure

MYQORZO reduces cardiac contractility, which can reduce LVEF and cause heart failure.

Patients who experience a serious intercurrent illness (eg, serious infection) or arrhythmia (eg, new or uncontrolled atrial fibrillation) may be at greater risk of developing systolic dysfunction and heart failure.

Assess patients’ clinical status and LVEF prior to and during treatment and adjust the MYQORZO dose accordingly. New or worsening arrhythmia, dyspnea, chest pain, fatigue, leg edema, or elevations in N-terminal pro-B-type natriuretic peptide may be signs and symptoms of heart failure.

Initiation of MYQORZO in patients with LVEF <55% is not recommended.

MYQORZO REMS Program

MYQORZO is available only through a restricted program called the MYQORZO REMS Program, because of the risk of heart failure due to systolic dysfunction.

Notable requirements of the MYQORZO REMS Program include:

• Prescribers must be certified by enrolling in the MYQORZO REMS Program
• Patients must enroll in the MYQORZO REMS Program and comply with ongoing monitoring requirements
• Pharmacies must be certified by enrolling in the MYQORZO REMS Program and must only dispense to patients who are authorized to receive MYQORZO
• Wholesalers and distributors must only distribute to certified pharmacies

Further information is available at www.MYQORZOREMS.com, or at 1-844-285-7367.

Cytochrome P450 Interactions Leading to Heart Failure or Loss of Effectiveness

MYQORZO is metabolized primarily by CYP2C9, and to a lesser extent by CYP3A, CYP2D6, and CYP2C19 enzymes. Initiation of medications that inhibit multiple P450 pathways of MYQORZO elimination (eg, fluconazole, voriconazole, or fluvoxamine) or strong CYP2C9 inhibitors, and discontinuation of moderate-to-strong CYP3A inducers may lead to increased blood concentrations of aficamten and increase the risk of heart failure due to systolic dysfunction. Conversely, initiation of medications that induce P450 pathways of MYQORZO (eg, rifampin, moderate-to-strong CYP3A inducers) may lead to decreased blood concentrations of aficamten and potential loss of effectiveness. Assess LVEF 2 to 8 weeks after initiation of such inhibitors or after discontinuation of such inducers and adjust the dose of MYQORZO accordingly.

Advise patients of the potential for drug interactions. Advise patients to inform their healthcare provider of all concomitant medications prior to and during MYQORZO treatment.

ADVERSE REACTIONS

Hypertension (8% vs 2%) was the only adverse reaction occurring in >5% of patients and more commonly on MYQORZO than on placebo in the pivotal trial.

Please see full Prescribing Information, including Boxed WARNING and Medication Guide.

About MYQORZO™ (aficamten)

MYQORZO™ (aficamten) is a cardiac myosin inhibitor approved by the U.S. FDA for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with HCM, myosin inhibition with MYQORZO reduces cardiac contractility and left ventricular outflow tract (LVOT) obstruction. MYQORZO was engineered to achieve a predictable exposure response, rapid onset of action and reversibility.²

On December 17, 2025, the China National Medical Products Administration approved MYQORZO® (aficamten) for the treatment of oHCM. On December 12, 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending marketing authorization in the European Union for MYQORZO® (aficamten) with a decision expected from the European Commission in the first quarter of 2026.

Aficamten is also under clinical investigation in ACACIA-HCM, a Phase 3 trial in patients with non-obstructive HCM (nHCM) and CEDAR-HCM, in a pediatric population with oHCM. Aficamten has not been deemed safe or effective for use in either of these patient populations. In addition, aficamten is being studied in FOREST-HCM, an open-label extension clinical study.

About Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle becomes abnormally thick. HCM can be obstructive, when thickened muscle blocks blood flow, or non-obstructive, when blood flow is not blocked but heart function is still affected. In obstructive HCM, the thickening of cardiac muscle leads to the inside of the left ventricle becoming smaller, stiffer and less able to relax and fill with blood. Ultimately, HCM limits the heart’s pumping function, leading to reduced exercise capacity and a variety of symptoms.

HCM is the most common monogenic inherited cardiovascular disorder, with well over 300,000 patients diagnosed in the U.S.³ However, there are an estimated 400,000-800,000 additional patients who remain undiagnosed.^4,5,6 Approximately half of patients with HCM have obstructive HCM (oHCM) and half have non-obstructive HCM (nHCM).³

People with HCM are at high risk of also developing cardiovascular complications including atrial fibrillation, stroke and mitral valve disease.⁷ People with HCM are at risk for potentially fatal ventricular arrhythmias and it is one of the leading causes of sudden cardiac death in younger people or athletes.⁸ A subset of patients with HCM are at high risk of progressive disease leading to dilated cardiomyopathy and heart failure necessitating cardiac transplantation.

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO™ (aficamten) is a cardiac myosin inhibitor approved for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms by the U.S. Food and Drug Administration and the China National Medical Products Administration. The Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending marketing authorization in the European Union for MYQORZO® (aficamten) with a decision expected from the European Commission in first quarter in 2026. Aficamten is also being studied for the potential treatment of non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to any of our clinical trials, statements relating to our ability to obtain regulatory approval for aficamten in any jurisdiction by any particular date, if ever. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval; Cytokinetics’ drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.

CYTOKINETICS^® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

MYQORZO^TM is a trademark of Cytokinetics in the U.S., and a registered trademark in the European Union.

MYQORZO & You ^TM is a trademark of Cytokinetics in the U.S.

References

1. Maron, MS, et al. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. doi:10.1056/NEJMoa2401424
2. Hartman JJ, Hwee DT, Roebrt-Paganin J, et al. Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy. Nat Cardiovasc Res. 2024;3(8) :1003-1016. doi:10.1038/s44161-024-00505-0
3. Butzner M, et al. Epidemiology of Hypertrophic Cardiomyopathy in the United States From 2016 to 2023. JACC Adv. 2026. 2026;5(2):102552. doi:10.1016/j.jacadv.2025.102552
4. CVrg: Heart Failure 2020-2029, p 44; Maron et al. 2013 doi:10.1016/S0140-6736(12)60397-3; Maron et al 2018 10.1056/NEJMra1710575
5. Symphony Health 2016-2021 Patient Claims Data DoF;
6. Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivotto I. Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. Am J Cardiol. 2016; 15;117(10):1651-1654.
7. Gersh, B.J., Maron, B.J., Bonow, R.O., Dearani, J.A., Fifer, M.A., Link, M.S., et al. 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Journal of the American College of Cardiology and Circulation, 58, e212-260.
8. Hong Y, Su WW, Li X. Risk factors of sudden cardiac death in hypertrophic cardiomyopathy. Current Opinion in Cardiology. 2022 Jan 1;37(1):15-21

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

FAQ

What is MYQORZO (aficamten) and what does it treat for CYTK?

MYQORZO is a once-daily oral cardiac myosin inhibitor indicated to improve functional capacity and symptoms in adults with symptomatic obstructive hypertrophic cardiomyopathy.

When did Cytokinetics (CYTK) receive FDA approval for MYQORZO?

The U.S. FDA approved MYQORZO on December 19, 2025.

What safety monitoring does MYQORZO (CYTK) require after starting treatment?

Echocardiogram assessments are required prior to and during treatment to monitor left ventricular ejection fraction (LVEF); initiation is not recommended if LVEF <55%.

How is MYQORZO distributed and who can prescribe it (CYTK)?

MYQORZO is available only through the MYQORZO REMS Program; prescribers, pharmacies, and patients must enroll and prescribers must be certified.

What are key drug-interaction concerns for MYQORZO (CYTK)?

MYQORZO is metabolized primarily by CYP2C9 and interactions with CYP inhibitors or inducers can raise heart-failure risk or reduce effectiveness; rifampin is contraindicated.

What strengths of MYQORZO are available for prescription in the U.S. (CYTK)?

MYQORZO is available in 5 mg, 10 mg, 15 mg, and 20 mg tablets for once-daily dosing.